

GROWTH HORMONE

Ipamorelin

Selective Growth Hormone Secretagogue

Selective ghrelin-receptor pentapeptide. Clean GH release with no cortisol or prolactin rise.

MECHANISM

Ghrelin receptor (GHS-R1a) agonist — selective pituitary GH secretagogue

DOSAGE

200–300 mcg 2–3x daily SC

HALF-LIFE

~2 hours

FORMAT

Lyophilised powder

BATCH

NU-IPA-2082

LOT

146082

CAS

170851-70-4

FORMULA

C38H49N9O5

ISSUED

2025-06-03

RETEST

2026-06-03

OVERVIEW

Ipamorelin is a selective pentapeptide growth-hormone secretagogue that mimics ghrelin's action at the GHS-R1a receptor to stimulate pulsatile GH release from pituitary somatotrophs. Its distinguishing feature is high selectivity — unlike GHRP-2 or GHRP-6, ipamorelin does not meaningfully raise cortisol, prolactin, or ACTH.

MECHANISM OF ACTION

Ghrelin receptor (GHS-R1a) agonist — selective pituitary GH secretagogue

KEY RESEARCH BENEFITS

- Selective GH release — no cortisol or prolactin rise
- Dose-dependent IGF-1 elevation
- Improved body composition and fat metabolism
- Enhanced sleep quality and recovery
- Well tolerated — minimal side-effect profile

RESEARCH NOTES

Multiple human trials confirm selective GH release without adrenal or lactotroph activation. Phase II studies in post-surgical recovery and sarcopenia completed.

STORAGE & STABILITY

Lyophilised: -20 °C, stable >=24 months. Reconstituted: 2–8 °C, use within 14 days.